As per the research report titled ‘Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global gastroesophageal reflux disease (GERD) therapeutics industry was valued at USD 5.5 billion in the year 2020 and is anticipated to grow significantly during 2021-2026.

The prime growth driver for the worldwide gastroesophageal reflux disease therapeutics industry is the rising consciousness of the ailment and its symptoms among the public.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4121730/  

For the record, growing pervasiveness of GERD is related to the rising cases of obesity, and poor lifestyle & diet habits. Various environmental factors and lifestyle progression with desk-bound habits, decreased dinner-to-bedtime, more dietary fat intake, recurrent smoking, and high alcohol consumption are also proven to leading disease causes. 

Rising incidents of heartburn will encourage the emergence of PPIs (protein pump inhibitors) and acid-reducing remedies. This factor, rise of GERD infections in developing countries, and technological developments for accelerated diagnosis of disease will propel the industry outlook.

Looking at the drug type segmentation of global gastroesophageal reflux disease therapeutics industry, categorization includes proton pump inhibitors, antacids, and H2 receptor blockers. Even though PPIs segment contribute a major industry share, but they offer a restricted amount of relief and weaken in about half a year.

On the other hand, acid blockers segmentation is poised to continue growing in the coming years, as the drug is the first choice of treatment for every physician as it is cost-effective and effective in managing GERD.

Moving towards the distribution channel, the market is segmented into online pharmacies, retail pharmacies, and hospital pharmacies.

Speaking of the regional scope, North American is estimated to contribute massively to industry growth during 2021-2026. This is due to rising cases of obesity-related GERD, aggressive drug development for GERD treatments & management, and higher spending capacity of individuals.

The topmost names in the global gastroesophageal reflux disease therapeutics industry include Merck & Co., EndoGastric Solutions Inc., Ironwood Pharmaceuticals Inc., Phathom Pharmaceuticals, Olympus Corporation, Takeda Pharmaceutical Company, CHEPLAPHARM Arzneimittel GmbH, Johnson & Johnson, Daewoong Pharmaceutical Co. Ltd., and Eisai Co. Ltd.